Cipla Sustainability
Sustainability
Our approach to responsible resource consumption, efforts to enhance access and affordability of medicines worldwide and strong financial growth, provide a robust foundation to build a responsible business.
8% CAGR
of Revenue over the last 5 Years
of Revenue over the last 5 Years
5.9% R&D Investment
₹ 22,753 Crores Revenue from Operations
Manufacturing Highlights
Our investments in manufacturing capital include development of new drug delivery systems, facilitation of infrastructure supporting API and formulation developments and strengthening of platform technologies.
30.54 Billion
Tablets and capsules
125.80 Million
Aerosol pMDI
1.63 Million
Lyophilised injections
773.60 Million
Repsules
48 Million
Nasal sprays
51.60 Million
Oral liquids
2.50 Million
Form-fill seal eye-drops
COMMITTEES
OF BOARD
Learn MoreOF BOARD
MILESTONE
AWARDS
Learn MoreAWARDS
